Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIKTORIA-2: Gedatolisib in HR+/HER2- Advanced Breast Cancer
NCT06757634Phase 3Recruiting
- Sponsor
- Celcuity Inc.
- Start
- Jul 2025
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of gedatolisib in breast cancer, sponsored by Celcuity Inc.. Started Jul 2025; status: recruiting.
02
Drugs
gedatolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06757634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757634.